Valvular & structural heart disease
Transcatheter aortic‐valve implantation with or without on‐site cardiac surgery: The TRACS trial
Study context
- Population
- Symptomatic severe AS, inoperable, at high surgical risk, or with ≥1 clinical factor compromising the benefit/risk ratio for emergent cardiac surgery (ECS)planned enrolment 566
- Planned comparison
- Transcatheter aortic valve implantation (TAVI) in centres without vs with on-site cardiac surgery
- Primary endpoint
- Composite of:
- All-cause death
- Stroke
- Hospital readmission for CV causes
- Follow-up
- 1 year
Methodological detailsdesign paper, prospective, multicentre, open-label, blinded adjudicated evaluation of outcomes, Safety endpoint: death attributable to periprocedural complications actionable by ECS
- Design paper
- Prospective
- Multicentre
- Open-label
- Blinded adjudicated evaluation of outcomes
- Safety endpoint: death attributable to periprocedural complications actionable by ECS
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Transcatheter aortic‐valve implantation with or without on‐site cardiac surgery: The TRACS trial. Am Heart J. Published 4 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →